These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24953046)

  • 1. Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
    Daida H; Nohara R; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    J Atheroscler Thromb; 2014; 21(7):739-54. PubMed ID: 24953046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
    Yamazaki T; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yokoi H; Yoshida M;
    Int Heart J; 2013; 54(1):33-9. PubMed ID: 23428922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study.
    Kurabayashi M; Sakuma I; Kawamori R; Daida H; Yamazaki T; Yoshida M; Hata M; Masuda I; Kaku K; Yokoi H; Kishimoto J; Nohara R
    J Atheroscler Thromb; 2010 Apr; 17(4):416-22. PubMed ID: 20215710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
    Yokoi H; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yoshida M
    Int Heart J; 2014; 55(2):146-52. PubMed ID: 24632963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2013; 77(6):1526-33. PubMed ID: 23486191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of intima-media thickness in subjects with asymptomatic carotid disease: two cases from the Asymptomatic Carotid Atherosclerosis DIsease Manfredonia Study (ACADIM Study).
    Riccioni G; D'Orazio N
    Clin Ter; 2007; 158(5):431-3. PubMed ID: 18062350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
    Crouse JR; Grobbee DE; O'Leary DH; Bots ML; Evans GW; Palmer MK; Riley WA; Raichlen JS;
    Cardiovasc Drugs Ther; 2004 May; 18(3):231-8. PubMed ID: 15229392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
    Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
    Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
    Yogo M; Sasaki M; Ayaori M; Kihara T; Sato H; Takiguchi S; Uto-Kondo H; Yakushiji E; Nakaya K; Komatsu T; Momiyama Y; Nagata M; Mochio S; Iguchi Y; Ikewaki K
    Atherosclerosis; 2014 Jan; 232(1):31-9. PubMed ID: 24401214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.